ClinicalTrials.gg
CompletedNCT04305041Updated Sep 1, 2026Results posted

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

A Phase 1/2 interventional study of Pembrolizumab and Quavonlimab in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Melanoma by Merck & Co., Inc — 1 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Merck & Co., Inc.

Enrollment
23rd of 39
100 · median 131
Started
2020
with 4 others
Phase 1/2
9 of 42
1 open now
Registered
33rd of 42
by date

Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 1/2, and was the 33rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 42 studies in Melanoma by Merck & Co., Inc is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Melanoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.

The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • receptor tyrosine kinase inhibitor
  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine receptor motif domains (TIGIT)
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed melanoma
  • Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy
  • Has progressed on treatment with an /L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies
  • Has imaging documenting progression per 1.1 and after initiation of an anti-PD-1/L1 agent, or by RECIST 1.1 if progression occurred on therapy or in the setting of rapid progression.
  • Has not received more than 3 for their advanced melanoma
  • Has provided a tumor
  • Male participants who receive lenvatinib or ATRA are abstinent from heterosexual intercourse or agree to use during the intervention period and for at least 7 days after the last dose of lenvatinib or ATRA; for male participants who only receive pembrolizumab, quavonlimab, vibostolimab, or a combination, no contraception measures are needed
  • Female participant are not pregnant or breastfeeding and are either not a woman of (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab, quavonlimab, vibostolimab or 30 days after the last dose of lenvatinib or ATRA, whichever occurs last
  • Has adequate organ function
  • Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency or is receiving therapy within 7 days before the first dose of study intervention
  • Has a known additional that is progressing or requires active treatment within the past 2 years
  • Has known central nervous system (CNS) and/or carcinomatous meningitis
  • Has ocular or mucosal melanoma
  • Has known including previous hypersensitivity reaction to treatment with another mAb
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has an active infection requiring systemic therapy
  • Has known history of (HIV)
  • Has known history of
  • Has a history of (noninfectious) pneumonitis
  • Has a history of active tuberculosis (TB)
  • Has received prior systemic anticancer therapy within 4 weeks prior to randomization
  • Has received prior radiotherapy within 2 weeks of first dose of study intervention
  • Has had major surgery \<3 weeks prior to first dose of study intervention
  • Has received a within 30 days before the first dose of study intervention
  • Has participated in a study of an agent within 4 weeks prior to the first dose of study intervention
  • Has had an allogeneic tissue/solid organ transplant
  • Has a pre-existing Grade ≥3 gastrointestinal fistula or nongastrointestinal fistula
  • Has radiographic evidence of encasement of invasion of major blood vessel or of intratumoral cavitation
  • Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study intervention
  • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Quavonlimab + Vibostolimab

    Participants will receive pembrolizumab intravenously (IV) plus quavonlimab IV plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab · Biological: Quavonlimab · Biological: Vibostolimab

  • Experimental
    Pembrolizumab + Quavonlimab + Lenvatinib

    Participants will receive pembrolizumab IV plus quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab · Biological: Quavonlimab · Drug: Lenvatinib

  • Experimental
    Pembrolizumab + all-trans retinoic acid (ATRA)

    Participants will receive pembrolizumab IV plus ATRA orally at specified doses on specified days for a total treatment duration of up to approximately 2 years

    Biological: Pembrolizumab · Drug: ATRA

Interventions

  • BiologicalPembrolizumab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-3475, KEYTRUDA®

  • BiologicalQuavonlimab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-1308

  • BiologicalVibostolimab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-7684

  • Administered via oral capsules at a specified dose on specified days

    Also known as: MK-7902, LENVIMA®

  • DrugATRA

    Administered via oral capsules at a specified dose on specified days

    Also known as: VESANOID

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE is reported.

    Time frame: Up to approximately 39 months

  2. Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to 35 months

  3. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)

    ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 95% CI was reported.

    Time frame: Up to approximately 59 months

  4. ORR Per RECIST 1.1 With 90% CI

    ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 90% CI was reported.

    Time frame: Up to approximately 59 months

Secondary outcomes

  1. Duration of Response (DOR) Per RECIST 1.1

    For participants in the analysis population who showed a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 59 months

07

Results

Posted Aug 13, 2026

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
Started404020
Completed000
Not completed404020
Withdrew: Death323316
Withdrew: Lost to follow-up100
Withdrew: Physician decision100
Withdrew: Sponsor decision663
Withdrew: Withdrawal by subject011

Outcome measures

PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced an AE is reported.

Time frame:
Up to approximately 39 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of ParticipantsPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
Percentage of Participants Who Experienced an Adverse Event (AE)97.5100.095.0
PrimaryPercentage of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

Time frame:
Up to 35 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Percentage of ParticipantsPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
Percentage of Participants Who Discontinued Study Treatment Due to an AE15.030.00.0
PrimaryObjective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)

ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 95% CI was reported.

Time frame:
Up to approximately 59 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)
Percentage of ParticipantsPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) With 95% Confidence Interval (CI)17.5 (7.3 to 32.8)27.5 (14.6 to 43.9)0.0 (0.0 to 16.8)
SecondaryDuration of Response (DOR) Per RECIST 1.1

For participants in the analysis population who showed a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurred first. Responses were according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 59 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1
MonthsPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
Duration of Response (DOR) Per RECIST 1.19.8 (4.1 to NA)14.8 (3.9 to NA)—
PrimaryORR Per RECIST 1.1 With 90% CI

ORR was defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 was modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Per protocol, ORR with 90% CI was reported.

Time frame:
Up to approximately 59 months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 With 90% CI
Percentage of ParticipantsPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
ORR Per RECIST 1.1 With 90% CI17.5 (8.5 to 30.4)27.5 (16.3 to 41.4)0.0 (0.0 to 13.9)

Adverse events

Collected over Up to approximately 59 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Quavonlimab + Vibostolimab32/40 (80%)11/40 (27.5%)39/40 (97.5%)
Pembrolizumab + Quavonlimab + Lenvatinib34/40 (85%)21/40 (52.5%)40/40 (100%)
Pembrolizumab + All-trans Retinoic Acid (ATRA)17/20 (85%)6/20 (30%)18/20 (90%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
ColitisGastrointestinal disorders0/403/400/20
AnaemiaBlood and lymphatic system disorders0/402/400/20
Acute coronary syndromeCardiac disorders0/402/400/20
Rectal haemorrhageGastrointestinal disorders0/400/401/20
SubileusGastrointestinal disorders0/400/401/20
Femoral neck fractureInjury, poisoning and procedural complications0/400/401/20
Alanine aminotransferase increasedInvestigations1/400/401/20
Aspartate aminotransferase increasedInvestigations0/400/401/20
HeadacheNervous system disorders0/400/401/20
Device occlusionProduct Issues0/400/401/20
Most frequent other events
Showing 10 of 67
Most frequent other events
EventPembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)
DiarrhoeaGastrointestinal disorders11/4023/402/20
HeadacheNervous system disorders1/4014/4011/20
HypertensionVascular disorders1/4022/400/20
DysphoniaRespiratory, thoracic and mediastinal disorders0/4018/400/20
Lipase increasedInvestigations3/4015/401/20
ArthralgiaMusculoskeletal and connective tissue disorders6/4015/404/20
HypothyroidismEndocrine disorders2/4014/400/20
Dry mouthGastrointestinal disorders4/4014/403/20
Decreased appetiteMetabolism and nutrition disorders8/4014/403/20
AstheniaGeneral disorders13/4013/404/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)Total
Mean61.3 ± 12.960.5 ± 13.461.8 ± 16.761.1 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)Total
Female1461030
Male26341070
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)Total
Hispanic or Latino0112
Not Hispanic or Latino28261872
Unknown or Not Reported1213126
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + Quavonlimab + VibostolimabPembrolizumab + Quavonlimab + LenvatinibPembrolizumab + All-trans Retinoic Acid (ATRA)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White36311784
More than one race0000
Unknown or Not Reported49316
08

Study locations

36 sites
  • The Angeles Clinic and Research Institute ( Site 1009)
    Los Angeles, California 90025, United States
  • UCLA Hematology & Oncology ( Site 1004)
    Los Angeles, California 90095, United States
  • Providence Saint John's Health Center ( Site 1010)
    Santa Monica, California 90404, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 1012)
    Aurora, Colorado 80045, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022)
    Baltimore, Maryland 21287, United States
  • NYU Clinical Cancer Center ( Site 1002)
    New York, New York 10016, United States
  • Duke Cancer Institute ( Site 1005)
    Durham, North Carolina 27710, United States
  • Martha Morehouse Tower ( Site 1020)
    Columbus, Ohio 43221, United States
  • Oregon Health & Science University ( Site 1013)
    Portland, Oregon 97239, United States
  • University of Pennsylvania Abramson Cancer Center ( Site 1008)
    Philadelphia, Pennsylvania 19104, United States
  • West Cancer Center - East Campus ( Site 1014)
    Germantown, Tennessee 38138, United States
  • University of Texas MD Anderson Cancer Center ( Site 1006)
    Houston, Texas 77030, United States
  • Inova Schar Cancer Institute ( Site 1011)
    Fairfax, Virginia 22031, United States
  • Calvary Mater Newcastle-Medical Oncology ( Site 1404)
    Waratah, New South Wales 2298, Australia
  • Melanoma Institute Australia ( Site 1402)
    Wollstonecraft, New South Wales 2065, Australia
  • Tasman Oncology Research Pty Ltd ( Site 1403)
    Southport, Queensland 4215, Australia
  • Fiona Stanley Hospital ( Site 1401)
    Murdoch, Western Australia 6150, Australia
  • Hopital La Timone ( Site 1103)
    Marseille, Bouches-du-Rhone 13005, France
  • Hopital Saint Andre ( Site 1108)
    Bordeaux, Gironde 33075, France
  • Institut Claudius Regaud ( Site 1105)
    Toulouse, Haute-Garonne 31059, France
  • Centre Hospitalier Lyon Sud ( Site 1102)
    Pierre-Bénite, Rhone 69495, France
  • A.P.H. Paris, Hopital Saint Louis ( Site 1107)
    Paris, 75010, France
  • Gustave Roussy ( Site 1101)
    Villejuif, Île-de-France Region 94805, France
  • HaEmek Medical Center ( Site 1703)
    Afula, 1834111, Israel
  • Rambam Health Care Campus-Oncology ( Site 1704)
    Haifa, 3109601, Israel
  • Hadassah Ein Karem Jerusalem ( Site 1702)
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center ( Site 1701)
    Ramat Gan, 5265601, Israel
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399)
    Milan, 20133, Italy
  • Istituto Europeo di Oncologia ( Site 1301)
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 1302)
    Naples, 80131, Italy
  • Istituto Oncologico Veneto IRCCS ( Site 1355)
    Padova, 35128, Italy
  • Policlinico Le Scotte - A.O. Senese ( Site 1377)
    Siena, 53100, Italy
  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE-Clinical Trials Unit ( Site 1865)
    Port Elizabeth, Eastern Cape 6055, South Africa
  • Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603)
    Geneva, Canton of Geneva 1211, Switzerland
  • CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)
    Lausanne, Canton of Vaud 1011, Switzerland
  • Universitaetsspital Zuerich ( Site 1601)
    Zuerich Flughafen, Canton of Zurich 8058, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Aug 2025, 61 months.

Results were first posted in Aug 2026, 11 months after primary completion.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 61 months is close to that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 12, 2020
StartActual
Jun 26, 2020
Primary completionActual
Aug 25, 2025
CompletionActual
Aug 25, 2025
Results first posted
Aug 13, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04305041
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Jun 26, 2020
Primary completion
Aug 25, 2025
Completion
Aug 25, 2025
Results posted
Aug 13, 2026
Last update
Sep 1, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quavonlimab · Vibostolimab · Lenvatinib · Tretinoin

Start the discussion